{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-059716","form_type":"8-K","ticker":"ARTV","cik":"0001817241","company_name":"Artiva Biotherapeutics, Inc.","filed_at":"2026-02-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.287182+00:00","generated_at":"2026-05-16T01:47:56.058306+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Artiva Biotherapeutics appoints former AbbVie SVP Elaine Sorg as Class I director","bullets":["Elaine Sorg appointed as Class I director on Feb 18, 2026, term expiring at 2028 annual meeting.","No arrangements or transactions requiring disclosure under Item 404(a) were identified.","Compensation includes $40k annual cash retainer and initial option for 27,500 shares; one-third vests immediately, remainder monthly over two years.","Automatic annual option grants of 13,750 shares on each annual meeting date vest on one-year anniversary or next annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-059716","json":"https://secwatch.observer/filing/0001193125-26-059716.json","markdown":"https://secwatch.observer/filing/0001193125-26-059716.md","text":"https://secwatch.observer/filing/0001193125-26-059716.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526059716/0001193125-26-059716-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526059716/artv-20250128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:47:56.058306+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}